173 related articles for article (PubMed ID: 38254155)
1. Distinct changes to pancreatic volume rather than pancreatic autoantibody positivity: insights into immune checkpoint inhibitors induced diabetes mellitus.
Wei HH; Lai YC; Lin G; Lin CW; Chang YC; Chang JW; Liou MJ; Chen IW
Diabetol Metab Syndr; 2024 Jan; 16(1):26. PubMed ID: 38254155
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
[TBL] [Abstract][Full Text] [Related]
3. Incidence of diabetes mellitus in patients treated with immune checkpoint inhibitors (ICI) therapy - A comprehensive cancer center experience.
Zhang Z; Sharma R; Hamad L; Riebandt G; Attwood K
Diabetes Res Clin Pract; 2023 Aug; 202():110776. PubMed ID: 37311494
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced diabetes mellitus.
Liu J; Shi Y; Liu X; Zhang D; Zhang H; Chen M; Xu Y; Zhao J; Zhong W; Wang M
Transl Oncol; 2022 Oct; 24():101473. PubMed ID: 35905639
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus Is Characterized by C-peptide Loss and Pancreatic Atrophy.
Wu L; Carlino MS; Brown DA; Long GV; Clifton-Bligh R; Mellor R; Moore K; Sasson SC; Menzies AM; Tsang V; Gunton JE
J Clin Endocrinol Metab; 2024 Apr; 109(5):1301-1307. PubMed ID: 37997380
[TBL] [Abstract][Full Text] [Related]
6. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
Yaura K; Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2021 Aug; 254(4):253-256. PubMed ID: 34373422
[TBL] [Abstract][Full Text] [Related]
7. Real-world adherence to toxicity management guidelines for immune checkpoint inhibitor-induced diabetes mellitus.
Shen M; Chen D; Zhao R; Zheng X; Gu Y; Yang T; Shi Y
Front Endocrinol (Lausanne); 2023; 14():1213225. PubMed ID: 37554766
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of insulinopenic and non insulinopenic diabetes related to immune checkpoint inhibitors: A French pharmacovigilance study.
Bastin M; Allouchery M; Sassier M; Rouby F; Eftekhari P; Lebrun-Vignes B; Andreelli F; Bihan K
Therapie; 2021; 76(6):695-703. PubMed ID: 33836905
[TBL] [Abstract][Full Text] [Related]
9. Type 1 diabetes associated with immune checkpoint inhibitors for malignant melanoma: A case report and review of 8 cases.
Ishiguro A; Ogata D; Ohashi K; Hiki K; Yamakawa K; Jinnai S; Tsutsui K; Takahashi A; Namikawa K; Yamazaki N
Medicine (Baltimore); 2022 Sep; 101(35):e30398. PubMed ID: 36107581
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab-induced diabetes mellitus-a case report with literature review of the treatment options.
Daetwyler E; Zippelius A; Danioth S; Donath MY; Gut L
Front Immunol; 2023; 14():1248919. PubMed ID: 37965350
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitor-Associated Diabetes: A Single-Institution Experience.
Byun DJ; Braunstein R; Flynn J; Zheng J; Lefkowitz RA; Kanbour S; Girotra M
Diabetes Care; 2020 Dec; 43(12):3106-3109. PubMed ID: 33051330
[TBL] [Abstract][Full Text] [Related]
12. Clinical and HLA genotype analysis of immune checkpoint inhibitor-associated diabetes mellitus: a single-center case series from China.
Liu YC; Liu H; Zhao SL; Chen K; Jin P
Front Immunol; 2023; 14():1164120. PubMed ID: 37359544
[TBL] [Abstract][Full Text] [Related]
13. A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome.
Marsiglio J; McPherson JP; Kovacsovics-Bankowski M; Jeter J; Vaklavas C; Swami U; Grossmann D; Erickson-Wayman A; Soares HP; Kerrigan K; Gibson B; Doherty JA; Hyngstrom J; Hardikar S; Hu-Lieskovan S
Front Immunol; 2023; 14():1229823. PubMed ID: 37671166
[TBL] [Abstract][Full Text] [Related]
14. Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports.
Zezza M; Kosinski C; Mekoguem C; Marino L; Chtioui H; Pitteloud N; Lamine F
BMC Endocr Disord; 2019 Dec; 19(1):144. PubMed ID: 31870373
[TBL] [Abstract][Full Text] [Related]
15. Type 1 diabetes mellitus affected by potential toxicity from long-term use of nivolumab.
Motomura Y; Urai S; Hirota Y; Takegawa N; Bando H; Yamamoto M; Fukuoka H; Tsuda M; Ogawa W
Diabetol Int; 2024 Jan; 15(1):130-134. PubMed ID: 38264226
[TBL] [Abstract][Full Text] [Related]
16. A Severe Case of Diabetic Ketoacidosis and New-Onset Type 1 Diabetes Mellitus Associated with Anti-Glutamic Acid Decarboxylase Antibodies Following Immunotherapy with Pembrolizumab.
Kedzior SK; Jacknin G; Hudler A; Mueller SW; Kiser TH
Am J Case Rep; 2021 Jun; 22():e931702. PubMed ID: 34185763
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes.
Kotwal A; Haddox C; Block M; Kudva YC
BMJ Open Diabetes Res Care; 2019; 7(1):e000591. PubMed ID: 30899528
[TBL] [Abstract][Full Text] [Related]
18. Checking the Checkpoint Inhibitors: A Case of Autoimmune Diabetes After PD-1 Inhibition in a Patient with HIV.
Hughes MS; Pietropaolo M; Vasudevan MM; Marcelli M; Nguyen H
J Endocr Soc; 2020 Dec; 4(12):bvaa150. PubMed ID: 33225197
[TBL] [Abstract][Full Text] [Related]
19. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group.
Grimmelmann I; Momma M; Zimmer L; Hassel JC; Heinzerling L; Pföhler C; Loquai C; Ruini C; Utikal J; Thoms KM; Kähler KC; Eigentler T; Herbst RA; Meier F; Debus D; Berking C; Kochanek C; Ugurel S; Gutzmer R;
Eur J Cancer; 2021 May; 149():1-10. PubMed ID: 33812141
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of immune checkpoint inhibitor diabetes mellitus at a comprehensive cancer center.
Jeun R; Iyer PC; Best C; Lavis V; Varghese JM; Yedururi S; Brady V; Glitza Oliva IC; Dadu R; Milton DR; Brock K; Thosani S
Immunotherapy; 2023 Apr; 15(6):417-428. PubMed ID: 37013834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
